Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
暂无分享,去创建一个
M. Rezai | P. Fasching | A. Schneeweiss | C. Denkert | H. Tesch | S. Loibl | I. Bauerfeind | M. Untch | J. Blohmer | S. Kümmel | G. von Minckwitz | J. Huober | C. Jackisch | C. Hanusch | S. Costa | H. Eidtmann | S. Paepke | B. Gerber | J. Hilfrich | K. Mehta | G. Minckwitz | P. Fasching | C. Denkert | Hans Tesch | B. Gerber | M. Untch
[1] William J. Gradishar,et al. Response-Guided Neoadjuvant Chemotherapy for Breast Cancer , 2013 .
[2] P. Fasching,et al. Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) , 2012 .
[3] P. Fasching,et al. Abstract S1-11: Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) , 2012 .
[4] P. Fasching,et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Zhen-zhou Shen,et al. First Efficacy Results of Capecitabine with Anthracycline- and Taxane-Based Adjuvant Therapy in High-Risk Early Breast Cancer: A Meta-Analysis , 2012, PloS one.
[6] V. Kataja,et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] F. Holmes,et al. Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer , 2010 .
[8] C. Denkert,et al. Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study , 2010, Breast Cancer Research and Treatment.
[9] Peter A Fasching,et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Rezai,et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] H. Tesch,et al. 24 Zoledronic acid (ZOL) as add-on therapy in patients with tumour residuals after neoadjuvant chemotherapy for primary breast cancer – first interim safety analysis of the NATAN study (GBG 36) , 2010 .
[12] P. Fasching,et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials , 2010, Breast Cancer Research and Treatment.
[13] V. Kataja,et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. , 2009, The Lancet. Oncology.
[14] Sally Hunsberger,et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.